Faculty profile

Bertrand Routy

ResearcherHematology-OncologyUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Bertrand Routy

Researcher

Hematology-Oncology

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
48 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Fecal Microbiota Transplantation Immune Checkpoint Inhibitors Microbiome Crc Cancer

Latest papers

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.
Gut microbes · 2026 · senior author
Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.
Nature · 2026
Toward Personalized Neoadjuvant Strategies: Using Metabolic and Biological Response to Guide Treatment Deescalation or Intensification.
The Annals of thoracic surgery · 2026

All 73 publications

Latest funding

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer
CIHR · 2025 · Nominated PI
$918,000
Finding the Perfect Time to Hunt for HIV: A Tale of 36 Hours at the CHUM
CIHR · 2023 · Co-investigator
$6,000
Canada Research Chair - Tier 2
CIHR · 2020 · Nominated PI
$600,000

All 4 grants and awards

73 publications.

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Benlaïfaoui M, Richard C, Hunter S, Méndez-Salazar EO, Kourtian S, Malo J, Prifti DK, Ponce M, Khalfi S, Belkaïd W, Messaoudene M, Boidot R, Truntzer C, Girhinghelli F, Lehoux-Duboix C, Ancuta P, Elkrief A, Marcil V, Routy B

Gut microbes2026Senior author

DOI: 10.1080/19490976.2026.2699457 PMID: 42454784

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Desharnais L, Swaby A, Messaoudene M, Doré S, Yu MW, Fiset B, Breton V, Ponce M, Hu Y, Wilson L, Sorin M, Wang Y, Dewar K, Pollak M, Elkrief A, Routy B, Walsh LA, Quail DF

Nature2026

DOI: 10.1038/s41586-026-10750-x PMID: 42420462

Toward Personalized Neoadjuvant Strategies: Using Metabolic and Biological Response to Guide Treatment Deescalation or Intensification.

Seitlinger J, Routy B, Liberman M, Spicer J

The Annals of thoracic surgery2026

DOI: 10.1016/j.athoracsur.2025.12.018 PMID: 41478328

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Brunetti L, Santo V, Pinato DJ, Citarella F, Orlando S, Acker F, Colella V, Ricciuti B, Naidoo J, Nassar A, Wakelee HA, Takada K, Naqash AR, Garassino MC, Greco C, Ramella S, Pantano F, Tonini G, Vincenzi B, Arlunno B, Remon J, Parisi C, Planchard D, Besse B, Desilets A, Routy B, Elkrief A, Barlesi F, Derosa L, Cortellini A

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(26)00191-9 PMID: 42398520

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Suissa D, Fidelle M, Reich E, Pham TN, Thomas S, Björk JR, Liu P, Zhao L, Kitaoka K, Piard E, Lebhar I, Tian AL, Thelemaque C, Alves Costa Silva C, Deutsch E, Loriot Y, Segata N, Piccinno G, Hospers GAP, Maleki Vareki S, Silverman MS, Lenehan JG, Bataille V, Boulate D, Kuznetsova T, Weersma RK, Messaoudene M, Durand S, van der Aalst CM, de Koning HJ, Schuler-Thurner B, de Vries IJM, Rafie E, Saliby RM, Machaalani M, Haferkamp S, Schilling B, Porcari S, Ciccarese C, Iacovelli R, Cremolini C, Choueiri TK, Elkrief A, Kroemer G, Heinzerling L, Chamoto K, Ianiro G, Routy B, Derosa L, Paragios N, Zitvogel L

Nature medicine2026

DOI: 10.1038/s41591-026-04481-9 PMID: 42350644

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Seitlinger J, Salko O, Bulgarelli Maqueda L, Meng A, Têtu M, Desilets A, Owen S, Shieh B, Wong A, Ofiara L, Agulnik J, Fiset PO, Malo J, Blais N, Florescu M, Tehfe M, Ferraro P, Nasir B, Cools-Lartigue J, Najmeh S, Juneau D, Elkrief A, Ferri L, Routy B, Liberman M, Spicer JD

The Annals of thoracic surgery2026

DOI: 10.1016/j.athoracsur.2025.09.051 PMID: 41167577

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Diop K, Benlaïfaoui M, Hunter S, Méndez-Salazar EO, Hakozaki T, Richard C, Prifti DK, Kourtian S, Proulx-Rocray F, Naimi S, Ponce M, Messaoudene M, Cauchois F, Belkaid W, Bataille V, Lee K, Mihalcioiu C, Watson IR, Elkrief A, Routy B

Microbiome2026Senior author

DOI: 10.1186/s40168-026-02419-4 PMID: 42083059

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Aouad S, Kadiri M, Allard D, Skora E, Giraud L, Fuselier C, Desroys du Roure P, Mousson A, Janvier A, Baron L, Franchet C, Lecru L, Routy B, Malo J, Brugat T, Blayo AL, Schann S, Stagg J

Journal for immunotherapy of cancer2026

DOI: 10.1136/jitc-2025-013507 PMID: 41932811

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Saber R, Tonneau M, Salko O, Liberman M, Malo J, Elkrief A, Turcotte S, Bouchard N, Joubert P, Kadoury S, Routy B

Cancers2026Senior author

DOI: 10.3390/cancers18040552 PMID: 41749806

Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038).

Isnard S, Berini CA, Parvathy SN, Feng H, Aiyana O, Royston L, Mabanga T, Lakatos PL, Bessissow T, Klein MB, Lebouché B, Costiniuk CT, Routy B, Silverman MS, Routy JP

Trials2025

DOI: 10.1186/s13063-025-09345-0 PMID: 41390455

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Fecal Microbiota Transplantation Dear Professor Routy, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Bertrand Routy

Research

Latest papers

Latest funding

Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Toward Personalized Neoadjuvant Strategies: Using Metabolic and Biological Response to Guide Treatment Deescalation or Intensification.

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer.

Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038).

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer

Finding the Perfect Time to Hunt for HIV: A Tale of 36 Hours at the CHUM

Canada Research Chair - Tier 2

Prebiotics to modify the gut microbiome and enhance immune checkpoint blockers

Frequent collaborators

Arielle Elkrief

Jean-Pierre Routy

Philippe Joubert

Jean-Pierre Routy

Nicolas Chomont

Houda Bahig

Bastien Castagner

Nicolas Chomont

John Stagg

Talat Bessissow

Thierry Muanza

Réjean Lapointe

Wilson Miller

David Roberge

Marie Hudson

Catalin Mihalcioiu

Mark Sorin

Philip Wong

Jesse Papenburg

Sareh Keshavarzi

Adrian Sacher

Pierre-Olivier Fiset

Jesse Papenburg

Alexander Lawandi

Jonathan Spicer

Cynthia Menard

Geoffrey Liu

Yves Brun

Jonathan Angel

Marina Klein

Gerald Batist

Gerald Batist

Petronela Ancuta

Lorenzo Ferri

Samuel Kadoury